Company registration number 02826793 (England and Wales)
PRESTIGE MEDICAL LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PRESTIGE MEDICAL LIMITED
CONTENTS
Page
Statement of financial position
1
Statement of changes in equity
2
Notes to the financial statements
3 - 12
PRESTIGE MEDICAL LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Non-current assets
Intangible assets
5
-
0
1,179
Property, plant and equipment
6
441,525
448,486
Deferred tax asset
12
298,467
312,780
739,992
762,445
Current assets
Inventories
7
961,509
714,522
Trade and other receivables
8
849,684
787,910
Cash and cash equivalents
88,767
93,156
1,899,960
1,595,588
Current liabilities
9
(4,143,551)
(3,419,089)
Net current liabilities
(2,243,591)
(1,823,501)
Total assets less current liabilities
(1,503,599)
(1,061,056)
Non-current liabilities
9
(260,220)
(322,201)
Net liabilities
(1,763,819)
(1,383,257)
Equity
Called up share capital
14
6,500,002
6,500,002
Retained earnings
(8,263,821)
(7,883,259)
Total equity
(1,763,819)
(1,383,257)

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the income statement within the financial statements.

The financial statements were approved by the board of directors and authorised for issue on 5 August 2026 and are signed on its behalf by:
Jennifer Whiteside
Director
Company registration number 02826793 (England and Wales)
PRESTIGE MEDICAL LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
Share capital
Retained earnings
Total
£
£
£
Balance at 1 January 2024
6,500,002
(7,851,039)
(1,351,037)
Year ended 31 December 2024:
Loss and total comprehensive income
-
(32,220)
(32,220)
Balance at 31 December 2024
6,500,002
(7,883,259)
(1,383,257)
Year ended 31 December 2025:
Loss and total comprehensive income
-
(380,562)
(380,562)
Balance at 31 December 2025
6,500,002
(8,263,821)
(1,763,819)
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
1
Accounting policies
Company information

Prestige Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is East House, Duttons Way, Shadsworth Business Park, Blackburn, Lancashire, BB1 2QR. The company's principal activities and nature of its operations are disclosed in the directors' report.

1.1
Basis of preparation

The financial statements have been prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework (FRS 101) and in accordance with applicable accounting standards.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, except for the revaluation of . The principal accounting policies adopted are set out below.

As permitted by FRS 101, the company has taken advantage of the following disclosure exemptions from the requirements of IFRS

The financial statements of the company are consolidated in the group accounts of Tuttnauer Limited. The group accounts of Tuttnauer Limited are available to the public and are available from its registered office.

1.2
Going concern

The company is reliant upon support from its parent and group companies. The directors have, at the time of approving the financial statements, a reasonable expectation that the company has adequate resources, supported by its parent company, to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements. true

 

In arriving at this assessment, the directors have obtained assurance from its parent company that support will continue to be provided as is appropriate by the parent and group and that no support provided to date by the parent and group will be withdrawn.

 

Although the company is showing a net liability and net current liability position as at 31 December 2025, £2,982,004 (2024 - £2,487,964) of the company's liabilities are owed to group companies, and are not subject to fixed repayment schedules. The company is fully owned by the Tuttnauer Group, which continues to support the company.

 

In light of the above the directors consider that there are no material uncertainties that lead to a significant doubt upon the company's ability to continue as a going concern. The directors have relied on the ongoing support of the parent group in making their assessment.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.3
Revenue

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reasonably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

 

The company does not expect to have any contracts where the period between the transfer of the promised good or services to the customer and payment by the customer exceeds one year. As a consequence, the company does not adjust any of the transaction prices for the time value of money.

 

Turnover from providing services is recognised in the accounting period in which the services are rendered.

 

Revenue of a standalone service is recognised at a point in time when the service is completed.

 

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 

1.4
Intangible assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

 

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

1.5
Property, plant and equipment

Property, plant and equipment are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Right-of-use leasehold property
10 years
Plant and equipment
3 to 15 years
Right-of-use motor vehicles
3 years
Right-of-use other assets
5 to 7 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the income statement.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.6
Impairment of tangible and intangible assets

At each reporting end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

 

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Inventories

Inventories are stated on a first in first out basis at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition.

 

Inventories held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

 

Inventories are measured on a first-in-first-out (FIFO) basis.

1.8
Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial assets

Financial assets are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets.

 

At initial recognition, financial assets classified as fair value through profit and loss are measured at fair value and any transaction costs are recognised in profit or loss. Financial assets not classified as fair value through profit and loss are initially measured at fair value plus transaction costs.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 6 -
Financial assets held at amortised cost

Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (eg trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary.

1.10
Financial liabilities

The company recognises financial debt when the company becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either 'financial liabilities at fair value through profit or loss' or 'other financial liabilities'.

Other financial liabilities

Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 7 -
1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of inventories or non-current assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.15
Leases
As lessee

At inception, the company assesses whether a contract is, or contains, a lease within the scope of IFRS 16. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Where a tangible asset is acquired through a lease, the company recognises a right-of-use asset and a lease liability at the lease commencement date. Right-of-use assets are included within property, plant and equipment, apart from those that meet the definition of investment property.

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the commencement date plus any initial direct costs and an estimate of the cost of obligations to dismantle, remove, refurbish or restore the underlying asset and the site on which it is located, less any lease incentives received.

 

The right-of-use asset is subsequently adjusted for remeasurements of the lease liability and applies the relevant cost model, fair value model or revaluation model as set out within the accounting policies for the applicable asset class. Where the cost model is applied, the asset is depreciated from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term, and is periodically reduced by impairment losses, if any.

The lease liability is initially measured at the present value of the lease payments that are unpaid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise fixed payments, variable lease payments that depend on an index or a rate, amounts expected to be payable under a residual value guarantee, and the cost of any options that the company is reasonably certain to exercise, such as the exercise price under a purchase option, lease payments in an optional renewal period, or penalties for early termination of a lease.

The lease liability is measured at amortised cost using the effective interest method. It is reassessed at each financial period end to reflect lease modifications and any changes to the factors considered at initial measurement, as set out above. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

The company has elected not to recognise right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less, or for leases of low-value assets including IT equipment. The payments associated with these leases are recognised in profit or loss on a straight-line basis over the lease term.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
2
Critical accounting estimates and judgements

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

 

Accounting estimates affecting the entity are the recognition of a deferred tax asset, stock provision and the interest rate used for discounting the right-of-use assets.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
30
30
4
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
109,890
114,197
Company pension contributions to defined contribution schemes
3,348
4,750
113,238
118,947

The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 1 (2024 - 1).

5
Intangible fixed assets
Software
Website
Total
£
£
£
Cost
At 31 December 2024
123,468
51,631
175,099
At 31 December 2025
123,468
51,631
175,099
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
5
Intangible fixed assets
Software
Website
Total
£
£
£
(Continued)
- 9 -
Amortisation and impairment
At 31 December 2024
122,289
51,631
173,920
Charge for the year
1,179
-
1,179
At 31 December 2025
123,468
51,631
175,099
Carrying amount
At 31 December 2024
1,179
-
1,179
6
Property, plant and equipment
Right-of-use leasehold property
Plant and equipment
Right-of-use motor vehicles
Right-of-use other assets
Total
£
£
£
£
£
Cost
At 1 January 2025
583,415
1,009,340
253,658
4,699
1,851,112
Additions
-
0
43,151
108,848
-
0
151,999
Disposals
-
0
-
0
(100,604)
-
0
(100,604)
At 31 December 2025
583,415
1,052,491
261,902
4,699
1,902,507
Accumulated depreciation and impairment
At 1 January 2025
292,088
979,874
128,784
1,880
1,402,626
Charge for the year
67,229
13,348
77,443
940
158,960
Eliminated on disposal
-
0
-
0
(100,604)
-
0
(100,604)
At 31 December 2025
359,317
993,222
105,623
2,820
1,460,982
Carrying amount
At 31 December 2025
224,098
59,269
156,279
1,879
441,525
At 31 December 2024
291,327
29,466
124,874
2,819
448,486
7
Inventories
2025
2024
£
£
Raw materials
426,242
363,658
Work in progress
-
15,701
Finished goods
535,267
335,163
961,509
714,522
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
8
Trade and other receivables
2025
2024
£
£
Trade receivables
253,529
727,221
Provision for bad and doubtful debts
(10,000)
(11,000)
243,529
716,221
Amounts owed by fellow group undertakings
521,885
13,104
Prepayments and accrued income
84,270
58,585
849,684
787,910
9
Liabilities
Current
Non-current
2025
2024
2025
2024
Notes
£
£
£
£
Trade and other payables
10
3,975,032
3,233,454
-
0
-
0
Taxation and social security
18,631
60,473
-
-
Lease liabilities
11
149,888
125,162
260,220
322,201
4,143,551
3,419,089
260,220
322,201
10
Trade and other payables
2025
2024
£
£
Trade payables
330,482
165,921
Amount owed to parent undertaking
1,387,141
2,409,319
Amounts owed to fellow group undertakings
1,594,863
78,645
Accruals and deferred income
640,465
579,569
Other payables
22,081
-
3,975,032
3,233,454
11
Lease liabilities
2025
2024
Net amounts due
£
£
Within one year
149,888
125,162
After more than one year
260,220
322,201
410,108
447,363
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
11
Lease liabilities
(Continued)
- 11 -
2025
2024
Maturity analysis of future lease payments
£
£
Within one year
149,888
125,162
In two to five years
260,220
322,201
Total undiscounted liabilities
410,108
447,363

 

The lease liabilities are secured by the assets to which they relate.

12
Deferred taxation
Assets
2025
2024
£
£
Deferred tax balances
298,467
312,780
Deferred tax assets are expected to be recovered after more than one year.

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon during the current and prior reporting period.

ACAs
Tax losses
Retirement benefit obligations
Total
£
£
£
£
Asset at 1 January 2024
44,463
266,126
2,191
312,780
Deferred tax movements in prior year
Credit/(charge) to profit or loss
(9,421)
11,612
(2,191)
-
Asset at 1 January 2025
35,042
277,738
-
0
312,780
Deferred tax movements in current year
Credit/(charge) to profit or loss
(14,313)
-
-
(14,313)
Asset at 31 December 2025
20,729
277,738
-
0
298,467

At the reporting end date the company has unused tax losses of £4,294,640 available for offset against future profits. A deferred tax asset has been recognised in respect of £1,110,952 of such losses. All losses are available against future profits and may be carried forward indefinitely.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 12 -
13
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
44,234
49,808

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

14
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
6,500,002
6,500,002
6,500,002
6,500,002
15
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
David Evans BA FCA
Statutory Auditor:
Bishops Audit Limited
Date of audit report:
5 August 2026
16
Related party transactions

The company is exempt from disclosing certain related party transactions as they are with other companies that are wholly owned within the group.

 

During the year the company purchased goods from its ultimate parent company and a fellow group subsidiary at discounted rates. Total purchases made from these companies in the year were £824,749 (2024 - £1,448,933)

17
Controlling party

The parent company is Tuttnauer Limited and the ultimate parent company and controlling party is Fortissimo Capital 4 Management Limited.

2025-12-312025-01-01Hagay AzaniAdil HamidJennifer WhitesideNir KinoryJohn PotterElad GinnatfalsefalseCCH SoftwareiXBRL Review & Tag 2025.2028267932025-01-012025-12-31028267932025-12-3102826793core:IntangibleAssetsOtherThanGoodwill2025-12-3102826793core:IntangibleAssetsOtherThanGoodwill2024-12-3102826793core:ComputerSoftware2024-12-31028267932024-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-12-3102826793core:PlantMachinery2025-12-3102826793core:MotorVehicles2025-12-3102826793core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-12-3102826793core:ContinuingOperations2025-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3102826793core:PlantMachinery2024-12-3102826793core:MotorVehicles2024-12-3102826793core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-12-3102826793core:AcceleratedTaxDepreciationDeferredTax2023-12-3102826793core:TaxLossesCarry-forwardsDeferredTax2023-12-3102826793core:RetirementBenefitObligationsDeferredTax2023-12-3102826793core:AcceleratedTaxDepreciationDeferredTax2024-12-3102826793core:TaxLossesCarry-forwardsDeferredTax2024-12-3102826793core:RetirementBenefitObligationsDeferredTax2024-12-3102826793core:AcceleratedTaxDepreciationDeferredTax2025-12-3102826793core:TaxLossesCarry-forwardsDeferredTax2025-12-3102826793core:RetirementBenefitObligationsDeferredTax2025-12-3102826793core:BetweenOneFiveYears2024-12-3102826793core:CurrentFinancialInstruments2025-12-3102826793core:CurrentFinancialInstruments2024-12-3102826793core:Non-currentFinancialInstruments2025-12-3102826793core:Non-currentFinancialInstruments2024-12-3102826793core:ShareCapital2025-12-3102826793core:ShareCapital2024-12-3102826793core:RetainedEarningsAccumulatedLosses2025-12-3102826793core:RetainedEarningsAccumulatedLosses2024-12-31028267932023-12-3102826793bus:Director32025-01-012025-12-3102826793core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3102826793core:RetainedEarningsAccumulatedLosses2025-01-012025-12-31028267932024-01-012024-12-3102826793core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-12-3102826793core:ComputerSoftware2025-12-3102826793core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-12-3102826793core:ComputerSoftware2024-12-31028267932024-12-3102826793core:ComputerSoftware2025-01-012025-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3102826793core:PlantMachinery2024-12-3102826793core:MotorVehicles2024-12-3102826793core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-01-012025-12-3102826793core:PlantMachinery2025-01-012025-12-3102826793core:MotorVehicles2025-01-012025-12-3102826793core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-01-012025-12-3102826793core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3102826793core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3102826793core:Non-currentFinancialInstrumentscore:AfterOneYear2025-12-3102826793core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3102826793bus:PrivateLimitedCompanyLtd2025-01-012025-12-3102826793bus:FRS1012025-01-012025-12-3102826793bus:Audited2025-01-012025-12-3102826793bus:Director12025-01-012025-12-3102826793bus:Director22025-01-012025-12-3102826793bus:Director42025-01-012025-12-3102826793bus:Director52025-01-012025-12-3102826793bus:Director62025-01-012025-12-3102826793bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3102826793bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP